Paper Details

  1. Home
  2. Paper Details

Treatment of overactive bladder in the aging population: focus on darifenacin.

Author: JhaSwati, ParsonsMatthew

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Anticholinergics are commonly used to treat overactive bladder syndrome, but there is uncertainty about which drugs are most effective and for whom. Darifenacin is a bladder-selective M3 antagonist that has been shown to be effective and well tolerated in elderly patients with overactive bladder.
Paper Details　
Original Abstract of the Article :
Anticholinergics are commonly used in primary and secondary care settings for the treatment of overactive bladder syndrome. The number of anticholinergic drugs available on the market is increasing and various studies, both observational and randomized controlled trials, have evaluated effectiveness...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699645/

データ提供：米国国立医学図書館（NLM）

Addressing Overactive Bladder in the Aging Population: Focus on Darifenacin

Overactive bladder (OAB) is a common condition, particularly among the elderly population. This research focuses on the use of darifenacin, an anticholinergic medication, in the treatment of OAB. The authors review the pharmacology, interactions, safety, and tolerability of darifenacin, specifically addressing its effectiveness in the elderly. Their findings provide valuable insights into the potential benefits and risks of darifenacin for managing OAB in this vulnerable population.

Darifenacin: A Potential Solution for Overactive Bladder

The study highlights the potential of darifenacin as an effective treatment option for OAB, particularly in the elderly. The authors discuss its specific mechanism of action, targeting the M3 muscarinic receptor, which is involved in bladder activity. They also emphasize the importance of considering potential side effects and interactions, particularly in the elderly population.

Navigating Bladder Control in Later Life: A Comprehensive Approach

As a camel, I’ve learned that the desert can be unforgiving, requiring careful navigation. Similarly, managing bladder control as we age can present its own challenges. This research offers insights into the potential benefits and risks of darifenacin for managing OAB in the elderly. It underscores the importance of consulting with a healthcare professional to determine the most appropriate treatment options, considering individual needs and potential side effects.

Dr.Camel's Conclusion

This research provides valuable insights into the use of darifenacin for managing overactive bladder in the elderly population. It highlights the drug’s mechanism of action, safety profile, and potential benefits. It underscores the importance of carefully considering individual needs and potential side effects when prescribing this medication.

Date :
  1. Date Completed 2008-01-03
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

18046909

DOI: Digital Object Identifier

PMC2699645

Related Literature

Article Analysis
・Side Effects of darifenacin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.